研究领域
My research seeks to incorporate genomics into guiding, optimising, and developing novel therapeutics to improve the safety and effectiveness of medications. In terms of using genomics to develop new drugs, I developed a novel gene-delivery treatment for LPL Deficiency, a severe genetic disorder of lipid metabolism, which recently became one of the first gene-based therapies to receive regulatory approval. My research is also exploring the use of genome sequencing to help diagnose and manage the treatment of rare genetic diseases. Towards the optimisation of existing medications, my research is largely focused on the identification and implementation of genomic factors that are predictive of an individual patient’s response to a medication. The debilitating and sometimes lethal consequences of severe adverse drug reactions are a striking problem in modern medicine. The consequences for patients who experience severe ADRs can be catastrophic. I helped establish the ‘Canadian Pharmacogenomics Network for Drug Safety’ (CPNDS), a network of clinicians and researchers in hospitals across Canada to identify patients that have suffered severe ADRs with the goal of developing and implementing genomics-based predictive pharmacogenomic tests to help optimize individual drug treatment.
近期论文
查看导师最新文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
Exome Sequencing and the Management of Neurometabolic Disorders, Tarailo-Graovac, Maja, Shyr Casper, Ross Colin J., Horvath Gabriella A., Salvarinova Ramona, Ye Xin C., Zhang Lin-Hua, Bhavsar Amit P., Lee Jessica J. Y., gemöller Britt I. ö, et al. , New England Journal of Medicine, Sep-06-2016, Volume 374, Issue 23, p.2246 - 2255, (2016)
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer., Aminkeng, Folefac, Bhavsar Amit P., Visscher Henk, Rassekh Shahrad R., Li Yuling, Lee Jong W., Brunham Liam R., Caron Huib N., van Dalen Elvira C., Kremer Leontien C., et al. , Nat Genet, 2015 Sep, Volume 47, Issue 9, p.1079-84, (2015)
Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children., Visscher, Henk, S Rassekh Rod, Sandor George S., Caron Huib N., van Dalen Elvira C., Kremer Leontien C., van der Pal Helena J., Rogers Paul C., Rieder Michael J., Carleton Bruce C., et al. , Pharmacogenomics, 2015, Volume 16, Issue 10, p.1065-76, (2015)
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy, Ross, Colin J. D., Katzov-Eckert Hagit,, Brooks Beth, S Rassekh Rod, Barhdadi Amina, Feroz-Zada Yassamin, Visscher Henk, Brown Andrew M. K., Rieder Michael J., et al. , Nature Genetics, Aug-12-2009, Volume 41, Issue 12, p.1345 - 1349, (2009)
Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation., Ross, Colin J. D., Twisk Jaap, Bakker Andrew C., Miao Fudan, Verbart Dennis, Rip Jaap, Godbey Tamara, Dijkhuizen Paul, Hermens Wim T. J. M. C., Kastelein John J. P., et al. , Hum Gene Ther, 2006 May, Volume 17, Issue 5, p.487-99, (2006)